<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951912</url>
  </required_header>
  <id_info>
    <org_study_id>yanbinye</org_study_id>
    <nct_id>NCT00951912</nct_id>
  </id_info>
  <brief_title>The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids</brief_title>
  <official_title>The Study of the Effects of Soy Isoflavones on the Metabolism of Glucose and Lipids in Postmenopausal Chinese Women With Impaired Glucose Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Nutrition Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Institute International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health of Guangdong Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies showed that soy foods or soy isoflavones can lower the risk of cardiovascular
      disease (CVD), osteoporosis and some cancers, but few human studies assessed effects of
      purified isoflavone components (genistein and daidzein) on glucose metabolism. This
      double-blinded, randomized, placebo-controlled trial will examine the effects of purified
      genistein and daidzein on glucose metabolism in prediabetic or diabetic women. One hundred
      and eighty eligible women age 30-70 years(without any treatment of diabetic drugs) will be
      recruited and randomly allocated into the following three arms: Placebo (10g isolated soy
      protein, ISP); Genistein (10g ISP + 50mg genistein); Daidzein (10g ISP + 50mg daidzein) per
      day for 6 mo. Fasting glucose, lipids, insulin, inflammation marks and post-load for glucose
      and insulin will be determined at 0, 3th, and 6th month. Changes in these indices will be
      compared among the three groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were Chinese adult women, age 30-70 year, with an FG concentration ranging from 5.6
      to 7.0 mmol/L or 2-h PG concentration ranging from 7.8-11.0 mmol/L or with newly diagnosed
      diabetes not requiring medication treatment according to a doctor's suggestion or
      participants did not willing to take medication themselves, and managed their diabetes just
      with a stable diet and exercise. Women were excluded if they had a history of coronary heart
      disease, stoke, thyroid disease, severe liver, lung, or gastrointestinal tract diseases; were
      currently or in the past 8 weeks used hypoglycemic or lipid-lowering or weight-reduction
      agents; were occurrence of diabetic complications; use of hormone replacement therapy;
      allergy to soy;were long-term antibiotics users.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Fasting Plasma Glucose</measure>
    <time_frame>Baseline,6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in 120-minutes Postload Plasma Glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in HbA1C</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in AUC of Glucose</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>values were from 75g glucose oral glucose tolerance test and caculated as (6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Fasting Plasma Insulin</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in HOMA-IR</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>HOMA-IR was calculated with the homeostasis model assessment for insulin resistance,and it is caculated as the following equation: HOMA-IR=FInsÃ—FG/22.5, where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in QUICKI</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>QUICKI is the abbreviation of Quantitative Insulin Sensitivity Check Index,and it is a marker to evaluate insulin sensitivity in HOMA model.It is calculated by using the following equation: 1/(logFIns +logFG),where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter.
The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Total Cholesterol</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Triglyceride</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in High Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change in Low Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>(6th month value-baseline value)/baseline value*100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Urinary Isoflavones</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Daidzein</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary daidzein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Genistein</measure>
    <time_frame>3 months</time_frame>
    <description>Urinary genistein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Energy Intake at Follow-up</measure>
    <time_frame>an average of the 24 weeks follow-up period which were evalutated on baseline,12 week and 24 week.</time_frame>
    <description>The energy intake was evaluated by 3 days dietary records.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10g soy protein isolated powder patch by mouth everyday for 6months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daidzein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genistein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10g soy protein isolated per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Daidzein</intervention_name>
    <description>50mg daidzein +10g soy protein isolated per day</description>
    <arm_group_label>Daidzein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Genistein</intervention_name>
    <description>50mg genistein +10g soy protein isolated per day</description>
    <arm_group_label>Genistein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese women aged 30-70 y

          -  Fasting glucose &gt;=5.6 mmol/l; post-load glucose &gt;=7.8 mmol/l

        Exclusion Criteria:

          -  Diabetes renal diseases

          -  Confirmed CVD, chronic liver,kidney diseases,Thyroid disease

          -  Medications affecting glucose or lipid metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-bin Ye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-ming Chen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <results_first_submitted>June 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 16, 2012</results_first_posted>
  <last_update_submitted>October 16, 2012</last_update_submitted>
  <last_update_submitted_qc>October 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>yanbinye</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>genistein</keyword>
  <keyword>daidzein</keyword>
  <keyword>impaired glucose regulation</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>lipids metabolism</keyword>
  <keyword>inflammation</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
    <mesh_term>Daidzein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>the recruitment period last about half a year,and the types of location are clinic of endocrinology and nutritional clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>the placebo group were given 10g soy protein isolated without isoflavones</description>
        </group>
        <group group_id="P2">
          <title>Daidzein</title>
          <description>Daidzein group were given 10g soy protein isolated and 50mg purify daidzein</description>
        </group>
        <group group_id="P3">
          <title>Genistein</title>
          <description>Genistein group were given 10g soy protein isolated and 50mg purify genistein</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other:Depression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Colon cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Stroke</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>the placebo group were given 10g soy protein isolated without isoflavones</description>
        </group>
        <group group_id="B2">
          <title>Daidzein</title>
          <description>Daidzein group were given 10g soy protein isolated and 50mg purify daidzein</description>
        </group>
        <group group_id="B3">
          <title>Genistein</title>
          <description>Genistein group were given 10g soy protein isolated and 50mg purify genistein</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.31" spread="11.07"/>
                    <measurement group_id="B2" value="56.36" spread="9.90"/>
                    <measurement group_id="B3" value="57.02" spread="9.68"/>
                    <measurement group_id="B4" value="56.57" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Fasting Plasma Glucose</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline,6 months</time_frame>
        <population>the number of participants for analysis was determined by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Fasting Plasma Glucose</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>the number of participants for analysis was determined by intention to treat</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="13.5"/>
                    <measurement group_id="O2" value="-1.00" spread="12.61"/>
                    <measurement group_id="O3" value="-4.89" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There are no difference in the difference of changes in plasma glucose.
Power calculation: The sample size of 55 subjects per group provided about 90% power to detect a significant change in the FG concentration of 8 mg/dL (7%) by using a general assumption of a 2-tailed a level of 0.05 and allowing for a 20% withdrawal rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7981</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.422</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6569</ci_lower_limit>
            <ci_upper_limit>5.0607</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.0842</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.411</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7486</ci_lower_limit>
            <ci_upper_limit>8.9171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.8823</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.399</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9234</ci_lower_limit>
            <ci_upper_limit>9.6881</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in 120-minutes Postload Plasma Glucose</title>
        <description>(6th month value-baseline value)/baseline*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>All participants were determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in 120-minutes Postload Plasma Glucose</title>
          <description>(6th month value-baseline value)/baseline*100%</description>
          <population>All participants were determinted by intention to treat</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.90" spread="20.67"/>
                    <measurement group_id="O2" value="-3.13" spread="20.60"/>
                    <measurement group_id="O3" value="-5.59" spread="24.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7696</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.2000</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9308</ci_lower_limit>
            <ci_upper_limit>8.3916</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6929</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1818</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4232</ci_lower_limit>
            <ci_upper_limit>10.8091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.4626</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1624</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6067</ci_lower_limit>
            <ci_upper_limit>12.5318</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in HbA1C</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants analyzed was determinted by intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in HbA1C</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants analyzed was determinted by intention to treat.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="7.17"/>
                    <measurement group_id="O2" value="-1.37" spread="5.99"/>
                    <measurement group_id="O3" value="-1.30" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.01174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.45967</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5428</ci_lower_limit>
            <ci_upper_limit>3.5194</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.68659</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.45320</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2020</ci_lower_limit>
            <ci_upper_limit>0.8288</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.67485</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.44646</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.174</ci_lower_limit>
            <ci_upper_limit>0.8243</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in AUC of Glucose</title>
        <description>values were from 75g glucose oral glucose tolerance test and caculated as (6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of patticipants was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in AUC of Glucose</title>
          <description>values were from 75g glucose oral glucose tolerance test and caculated as (6th month value-baseline value)/baseline value*100%</description>
          <population>The number of patticipants was determinted by intention to treat</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="14.06"/>
                    <measurement group_id="O2" value="-3.27" spread="16.98"/>
                    <measurement group_id="O3" value="-5.24" spread="17.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.9661</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.14977</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5857</ci_lower_limit>
            <ci_upper_limit>4.6535</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>-0.9972</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13581</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5830</ci_lower_limit>
            <ci_upper_limit>6.5886</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.9689</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.12126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5817</ci_lower_limit>
            <ci_upper_limit>9.5195</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Fasting Plasma Insulin</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Fasting Plasma Insulin</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants was determinted by intention to treat</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.27" spread="114.23"/>
                    <measurement group_id="O2" value="21.41" spread="91.23"/>
                    <measurement group_id="O3" value="6.06" spread="78.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Mean Rank</param_type>
            <param_value>1.442</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in HOMA-IR</title>
        <description>HOMA-IR was calculated with the homeostasis model assessment for insulin resistance,and it is caculated as the following equation: HOMA-IR=FInsÃ—FG/22.5, where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in HOMA-IR</title>
          <description>HOMA-IR was calculated with the homeostasis model assessment for insulin resistance,and it is caculated as the following equation: HOMA-IR=FInsÃ—FG/22.5, where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.83" spread="107.41"/>
                    <measurement group_id="O2" value="21.60" spread="98.88"/>
                    <measurement group_id="O3" value="-0.22" spread="64.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Mean Ranks</param_type>
            <param_value>1.895</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in QUICKI</title>
        <description>QUICKI is the abbreviation of Quantitative Insulin Sensitivity Check Index,and it is a marker to evaluate insulin sensitivity in HOMA model.It is calculated by using the following equation: 1/(logFIns +logFG),where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter.
The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in QUICKI</title>
          <description>QUICKI is the abbreviation of Quantitative Insulin Sensitivity Check Index,and it is a marker to evaluate insulin sensitivity in HOMA model.It is calculated by using the following equation: 1/(logFIns +logFG),where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter.
The percentage change was caculated as (6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="19.47"/>
                    <measurement group_id="O2" value="0.18" spread="15.60"/>
                    <measurement group_id="O3" value="6.29" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Mean Ranks</param_type>
            <param_value>2.169</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Total Cholesterol</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Cholesterol</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="40.06"/>
                    <measurement group_id="O2" value="-0.59" spread="11.90"/>
                    <measurement group_id="O3" value="-0.64" spread="15.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.4370</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9113</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.444</ci_lower_limit>
            <ci_upper_limit>15.318</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.4809</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8896</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3475</ci_lower_limit>
            <ci_upper_limit>15.3092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0439</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8669</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7296</ci_lower_limit>
            <ci_upper_limit>11.8174</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Triglyceride</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Triglyceride</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="45.50"/>
                    <measurement group_id="O2" value="3.43" spread="38.90"/>
                    <measurement group_id="O3" value="-1.56" spread="39.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
            <param_type>Mean ranks</param_type>
            <param_value>1.031</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in High Density Lipoprotein Cholesterol</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in High Density Lipoprotein Cholesterol</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="20.40"/>
                    <measurement group_id="O2" value="1.36" spread="15.21"/>
                    <measurement group_id="O3" value="2.15" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.8185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.2343</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0057</ci_lower_limit>
            <ci_upper_limit>9.6426</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0276</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.2199</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7619</ci_lower_limit>
            <ci_upper_limit>8.8170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7909</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.2050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5442</ci_lower_limit>
            <ci_upper_limit>6.9624</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Low Density Lipoprotein Cholesterol</title>
        <description>(6th month value-baseline value)/baseline value*100%</description>
        <time_frame>Baseline, 6 months</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Low Density Lipoprotein Cholesterol</title>
          <description>(6th month value-baseline value)/baseline value*100%</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="24.46"/>
                    <measurement group_id="O2" value="-0.93" spread="21.21"/>
                    <measurement group_id="O3" value="1.86" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1686</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0721</ci_lower_limit>
            <ci_upper_limit>12.0964</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7716</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1501</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8111</ci_lower_limit>
            <ci_upper_limit>9.2679</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.7837</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1309</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7767</ci_lower_limit>
            <ci_upper_limit>7.2092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Urinary Isoflavones</title>
        <time_frame>3 months</time_frame>
        <population>The number of participants for analysis was determinted by the participants who provided the urine samples at the 3-month test.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Urinary Isoflavones</title>
          <population>The number of participants for analysis was determinted by the participants who provided the urine samples at the 3-month test.</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.538" spread="10.153"/>
                    <measurement group_id="O2" value="25.818" spread="31.780"/>
                    <measurement group_id="O3" value="15.467" spread="22.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4437</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1001</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6416</ci_lower_limit>
            <ci_upper_limit>-0.2458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1986</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09986</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3956</ci_lower_limit>
            <ci_upper_limit>-0.0016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2451</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09648</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0544</ci_lower_limit>
            <ci_upper_limit>0.4358</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Daidzein</title>
        <description>Urinary daidzein excretion</description>
        <time_frame>3 months</time_frame>
        <population>The number of participants for analysis was determinted by the number of participants who provided urine samples at the 3-month test</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Daidzein</title>
          <description>Urinary daidzein excretion</description>
          <population>The number of participants for analysis was determinted by the number of participants who provided urine samples at the 3-month test</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="4.81"/>
                    <measurement group_id="O2" value="11.80" spread="11.14"/>
                    <measurement group_id="O3" value="3.73" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6353</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1146</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8617</ci_lower_limit>
            <ci_upper_limit>-0.4089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0282</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1156</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2003</ci_lower_limit>
            <ci_upper_limit>0.2568</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6635</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1121</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4419</ci_lower_limit>
            <ci_upper_limit>0.8851</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Genistein</title>
        <description>Urinary genistein excretion</description>
        <time_frame>3 months</time_frame>
        <population>The number of participants for analysis was determinted by the number of participants who supplied the urine samples at the 3-month test</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Genistein</title>
          <description>Urinary genistein excretion</description>
          <population>The number of participants for analysis was determinted by the number of participants who supplied the urine samples at the 3-month test</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.72"/>
                    <measurement group_id="O2" value="1.89" spread="2.59"/>
                    <measurement group_id="O3" value="6.54" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1557</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3911</ci_lower_limit>
            <ci_upper_limit>0.0796</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6060</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8414</ci_lower_limit>
            <ci_upper_limit>-0.3707</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4503</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1163</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6804</ci_lower_limit>
            <ci_upper_limit>-0.2202</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Energy Intake at Follow-up</title>
        <description>The energy intake was evaluated by 3 days dietary records.</description>
        <time_frame>an average of the 24 weeks follow-up period which were evalutated on baseline,12 week and 24 week.</time_frame>
        <population>The number of participants for analysis was determinted by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>All participants were received 10g soy protein isolated without isoflavones daily</description>
          </group>
          <group group_id="O2">
            <title>Daidzein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify daidzein daily</description>
          </group>
          <group group_id="O3">
            <title>Geinstein Group</title>
            <description>All participants were received 10g soy protein isolated plus 50mg purify genistein daily</description>
          </group>
        </group_list>
        <measure>
          <title>Total Energy Intake at Follow-up</title>
          <description>The energy intake was evaluated by 3 days dietary records.</description>
          <population>The number of participants for analysis was determinted by intention to treat</population>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1575" spread="575"/>
                    <measurement group_id="O2" value="1473" spread="294"/>
                    <measurement group_id="O3" value="1579" spread="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>102.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>83.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-99.3</ci_lower_limit>
            <ci_upper_limit>304.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>82.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-203.7</ci_lower_limit>
            <ci_upper_limit>196.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-106.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>82.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-305.1</ci_lower_limit>
            <ci_upper_limit>92.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>We collected 10 cases of other adverse events which were mild to moderate in severity in the 6 months intervention period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>the placebo group were given 10g soy protein isolated without isoflavones</description>
        </group>
        <group group_id="E2">
          <title>Daidzein</title>
          <description>Daidzein group were given 10g soy protein isolated and 50mg purify daidzein</description>
        </group>
        <group group_id="E3">
          <title>Genistein</title>
          <description>Genistein group were given 10g soy protein isolated and 50mg purify genistein</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperplasia of mammary glands</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>thirsty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vignal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A relative long time of recruitment leading to a little different in dietary intakes among subjects;The menstrual period will leading to different estradiol;The different severity of the diabetes leading to the different dropout percentage.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Yan-bin Ye</name_or_title>
      <organization>the First Affiliated Hospital of Sun Yat-sen University</organization>
      <phone>8620-87755766 ext 8179</phone>
      <email>yanbinye72@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

